Consolidated statements of operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 509,338	$ 537,840	$ 535,031
Cost of revenues	128,280	114,867	114,877
Gross profit	381,058	422,973	420,154
Operating costs and expenses:
Research, development and clinical studies	223,062	206,085	201,303
Sales and marketing	226,809	173,658	137,057
General and administrative	164,057	132,753	126,127
Total operating costs and expenses	613,928	512,496	464,487
Operating income (loss)	(232,870)	(89,523)	(44,333)
Financial (expenses) income, net	41,130	7,677	(7,742)
Total income (loss) before income taxes	(191,740)	(81,846)	(52,075)
Income tax	15,303	10,688	6,276
Net income (loss)	$ (207,043)	$ (92,534)	$ (58,351)
Basic net income (loss) per ordinary share (in usd per share)	$ (1.95)	$ (0.88)	$ (0.56)
Diluted net income (loss) per ordinary share (in usd per share)	$ (1.95)	$ (0.88)	$ (0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	106,391,178	104,660,476	103,433,274
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	106,391,178	104,660,476	103,433,274